Cytokinetics, Incorporated (CYTK)
NEUTRALFondamentale
32
Prezzo
$77.59
Capitalizzazione
$10.70B
Parte 1 · Quanto vale l'azienda
Panoramica
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Per questa società non c'è ancora una scheda redazionale
Concorrenti diretti
Con chi questa società si contende gli stessi clienti
Per questa società non c'è ancora una scheda redazionale
Per questa società non c'è ancora un elenco di concorrenti.
Stato Patrimoniale e Liquidità
Ricavi
$68M
Ultimi 12 mesi (al 30/06/2026)
Utile Netto
$-894M
Ultimi 12 mesi (al 30/06/2026)
Free Cash Flow
$-535M
Patrimonio Netto Totale
$-660M
Passività Totali
$2.08B
Rapporto di Liquidità
6.66
Copertura Interessi
13.43
Debito/EBITDA
-
Utile per Azione
Ricavi e Utile Netto
Free Cash Flow
Scomposizione Ricavi
Prospetto storico
Margini nel tempo
Il debito nel tempo
Quanto pesa il debito
Griglia della crescita
Crescita — Ricavi
Stima del Fair Value
Fair Value
$65.59
Prezzo Attuale
$77.59
Margine di Sicurezza
-18.3%
Range Fair Value
$42.64 - $88.55
Metodi di Stima
Metriche di Valutazione
Rapporto P/E
-
ROE
119.0%
Rapporto P/B
-
P/FCF
-
Margine Lordo
-
ROIC
-32.1%
Radar Redditività
Creazione di Valore (Vantaggio Competitivo)
ROIC
-32.1%
WACC
8.0%
ROIC − WACC
-40.1 pp
Il ROIC è sotto il costo del capitale: l'azienda distrugge valore per ogni dollaro investito.
Criteri di Analisi Fondamentale
Superati (6)
- Price CAGR 20.26%
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 9.6%
- Analyst Consensus 89% Buy
Non superati (11)
- EPS shows upward trend
- ROIC -32.1%
- Operating Margin -1046.1%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -131.2%
- Earnings Surprise avg -12.0%
- Share Dilution 7.1%
- Net Margin Trend -1321.1% vs -707.2%
- Piotroski F-Score 2/9
Non disponibili (10)
- Gross Margin NaN%
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Preoccupazioni finanziarie serie
Qualità degli Utili
Bassa qualità: indagare la contabilità
Diluizione Azionaria
Emissione nuove azioni, diluizione proprietà
Governance
Team Dirigenziale
| Nome | Ruolo | Età |
|---|---|---|
| Mr. Robert I. Blum | CEO, President & Director | 61 |
| Mr. Sung H. Lee | EVP & CFO | 55 |
| Mr. Jeffrey J. Hessekiel J.D. | Executive VP, Chief Legal & Administrative Officer | 56 |
| Dr. Fady Ibraham Malik FACC, M.D., Ph.D. | Executive Vice President of Research & Development | 61 |
| Mr. Andrew M. Callos | Executive VP & Chief Commercial Officer | 56 |
| Dr. James H. Sabry M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 67 |
| Dr. James A. Spudich Ph.D. | Co-Founder & Member of Scientific Advisory Board | 83 |
| Mr. Jeff Lotz | Vice President of Sales & Operations | - |
| Ms. Holly Laughlin | VP of Accounting & Corporate Controller | - |
| Mr. Steven M. Cook J.D. | Senior Vice President of Global Supply Chain Operations & Technical Operations | 66 |
Rischio Audit
5
Rischio CdA
3
Rischio Compensi
8
Rischio Diritti Azionisti
7
Parte 2 · Il prezzo e il momento d'ingresso
Questa parte non serve a capire se l'azienda vale: serve a scegliere quando comprarla, dopo che i fondamentali ti hanno convinto. Dentro: analisi tecnica, potenziale, drawdown storici, esposizione gamma.
Ultime Notizie
Ultime notizie per CYTK, da Markets Gazette.
- 3/9/2026POSITIVECytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
A significant insider transaction at Cytokinetics Inc. has been reported, with an executive exercising stock options valued at over $920,000. This occurs as the company's cardiac drug candidate progresses towards market entry. The exercise of options by an insider often signals confidence in the company's future prospects and the value of its stock. Coupled with the impending market launch of a key therapeutic, this event suggests positive momentum for Cytokinetics, potentially attracting further investor interest and supporting share price appreciation.
- 2/24/2026NEUTRALCytokinetics (CYTK) Q4 2025 Earnings Transcript
The financial community is keenly awaiting the Q4 2025 earnings transcript from Cytokinetics (CYTK). While specific details are not yet available, the analysis of such documents is crucial for investors looking to assess the biopharmaceutical company's operational performance and future prospects. Transcripts offer direct insights into management discussions regarding financial results, drug pipeline advancements, and growth strategies. Analysts will closely monitor any indications concerning key drugs like omecamtiv mecarbil or aficamten, as well as projections for the current fiscal year. The current lack of specific data suggests a cautious approach, but the release is a standard event providing transparency and a basis for informed decisions.
via Markets Gazette